NOVARTIS AG (NVS)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Annual

0 20B 40B 60B FY24: 50.3B FY25: 54.5B FY24 FY25

Gross Profit Annual

0 15B 30B 45B FY24: 38.9B FY25: 43B FY24 FY25

Operating Income Annual

0 6B 12B 18B FY24: 14.5B FY25: 17.6B FY24 FY25

Net Income Annual

0 5B 10B 15B FY24: 11.9B FY25: 14B FY24 FY25

Cost of Revenue Annual

0 5B 10B 15B FY24: 12.8B FY25: 13.7B FY24 FY25

Operating Cash Flow Annual

0 7B 14B 21B FY24: 17.6B FY25: 19.1B FY24 FY25

Free Cash Flow Annual

0 6B 12B 18B FY24: 16.3B FY25: 17.6B FY24 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

EPS TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.